AstraZeneca Adds Intellipharmaceutics To Seroquel Row

Law360, New York (May 25, 2011, 3:26 PM EDT) -- AstraZeneca Pharmaceuticals LP hit Intellipharmaceutics Corp. with a suit Monday in New Jersey federal court, adding the company to the list of generic-drug makers accused of infringing a patent for schizophrenia and bipolar drug Seroquel XR.

AstraZeneca said Intellipharmaceutics sent a notice letter earlier this month disclosing that it had submitted an abbreviated new drug application to the U.S. Food and Drug Administration seeking approval to make and sell generic versions of Seroquel XR in a range of doses from 150 milligrams to 400 mg and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.